Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 4/20 | 0.52 |
| ▸ | CDK8 | P49336 | 3/20 | 0.52 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13746314 | 0.86 | DYRK1A (0.49) | AXLCDK8TNIKBRD4KIT | |
| SCHEMBL8321781 | 0.83 | AXL (0.52) | AXLCDK8TNIKBRD4DYRK1A | |
| SCHEMBL8323580 | 0.81 | AXL (0.55) | AXLCDK8TNIKNTRK1KIT | |
| SCHEMBL1800807 | 0.80 | AXL (0.73) | AXLCDK8TNIKNTRK1GSK3B | |
| SCHEMBL8321385 | 0.80 | KIT (0.59) | NTRK1KITDYRK1A | |
| SCHEMBL12764153 | 0.80 | AXL (0.46) | AXLCDK8TNIKNTRK1GSK3B | |
| SCHEMBL4209183 | 0.80 | CYP11B1 (0.49) | AXLCDK8TNIKNTRK1GSK3B | |
| SCHEMBL8320981 | 0.79 | CDK8 (0.73) | AXLCDK8TNIKNTRK1KIT | |
| SCHEMBL8323599 | 0.78 | CDK8 (0.52) | AXLCDK8TNIKKITDYRK1A | |
| SCHEMBL8320542 | 0.78 | DYRK1A (0.59) | AXLCDK8TNIKBRD4NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| WO-2004078756-A2 | JNK INHIBITORS | EISAI CO., LTD. (JP) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | AXL 3999/4885CDK8 360/4885TNIK 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.